BY MEGAN BROOKS
New research supports the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for Alzheimer’s disease (AD).
In a 52-week phase 2 trial, personalized rTMS applied over the precuneus, a core component of the default mode network (DMN), slowed the progression of cognitive and functional decline in patients with mild to moderate AD.
As reported previously by Medscape Medical News, the 52-week results align with the results seen at 24 weeks.
READ FULL ARTICLE HERE
The post Personalized Noninvasive Neuromodulation Slows AD Progression first appeared on Sinaptica Therapeutics™.